25 results about "Scatchard plot" patented technology

The invention relates to a UCNPs probe-based in-situ dynamic monitoring molecular interaction method, which comprises: S1, providing a UCNPs probe, the core layer of the UCNPs probe being a rare earth up-conversion nanocrystal, the shell layer of the UCNPs probe being an anti-quenching inert material, and the anti-quenching inert material coating the surface of the rare earth up-conversion nanocrystal; the surface of the anti-quenching inert material is modified with ligand molecules, and the ligand molecules are used for being specifically combined with target molecules in a to-be-detected sample; s2, mixing or contacting the UCNPs probe with a to-be-detected sample containing target molecules to construct a to-be-analyzed molecular interaction system; s3, irradiating the molecular interaction system by adopting near-infrared pulse laser, and collecting the change of the fluorescence lifetime tau of the UCNPs along with the time t and the change of the fluorescence intensity I along with the time t in real time to obtain a tau-t curve and an I-t curve; and S4, according to the tau-t curve and the I-t curve, realizing in-situ dynamic monitoring on the molecular interaction state. According to the method, a molecular binding / dissociation event is directly converted into a quantifiable and anti-interference optical signal, and the technical defect that in-situ dynamic monitoring of molecular interaction cannot be achieved in a traditional technology is overcome.

Provided are a method and system for predicting an activation potency of agonist molecules on G Protein-Coupled Receptors (GPCRs). The method includes: blindly speculating complex structures formed by binding of a ligand to an activated receptor structure and an inactivated receptor structure, respectively, via global molecular docking; extracting an initial path enabling an inactivated complex structure to be activated to an activated complex structure based on an enhanced sampling algorithm; searching for a minimum free energy path closest to the initial path by applying an automatic path optimization algorithm; calculating a free energy distribution curve along the minimum free energy path by employing umbrella sampling and determining an energy barrier height and a free energy difference before and after activation, thereby determining the activation potency of the ligand structure on the GPCRs.

The invention belongs to the technical field of molecular biology, and particularly relates to a standard substance for detecting absolute telomere length and a preparation method and application thereof. The standard substance provided by the invention exists in the form of plasmids, and comprises a telomere standard substance and a single copy gene IFNB1 standard substance. The specific standard substance for detecting the absolute telomere length has good and stable amplification efficiency, and the standard curve stability of the standard substance is high.

This invention discloses a shark-derived single-domain antibody that binds to hemoglobin and its application. The nucleotide sequence of the single-domain antibody is labeled SEQ ID NO.1, while the corresponding amino acid sequence is recorded as SEQ ID NO.2. The shark-derived single-domain antibody is used to detect hemoglobin concentration. The detection method includes setting up a standard group and a sample group, then adding the shark-derived single-domain antibody to the immunoassay plates of the standard group and the sample group, and measuring the OD of the standard group and the sample group after color development. 450 Value, based on the OD of the standard group 450 Values, plot OD 450 The standard curve is calculated based on the OD value. 450 The standard curve was used to obtain the hemoglobin concentration of the sample group. The single-domain antibody prepared in this invention exhibits good stability, high specificity, and high affinity. The antibody screened in this invention provides a theoretical basis and technical support for the subsequent diagnosis and monitoring of hemoglobin-targeted diseases.

According to the present invention, a method is provided for determining kinetic parameters of a reaction between an analyte and a ligand attached to a test surface of a flow cell, the method comprising the steps of: (a) flowing a first volume of sample fluid (V1) containing the analyte through the test surface between a first time point (t1) and a second time point (t2); (b) flowing a first volume of buffer fluid (Vb1) without the analyte through the test surface between a third time point (t3) and a fourth time point (t4); (c) flowing a sample fluid (V2) containing at least a second volume of the analyte through the test surface between a fifth time point (t5) and a sixth time point (t6); (d) flowing a buffer fluid (Vb2) without the analyte through the test surface between a seventh time point (t7) and an eighth time point (t8); (e) measuring the binding of the analyte to the ligand on the test surface using a sensor to obtain a binding curve; and (f) using only a portion of the binding curve within a predefined time interval and excluding other portions of the binding curve to determine the kinetic parameters.

The invention relates to the technical field of blood analysis, in particular to a scatter diagram-based lipid particle identification method and a blood cell analyzer. The method comprises the following steps: extracting lipid particle characteristics in a three-dimensional scatter diagram of a blood sample to obtain sample curve characteristics and particle number characteristics, and obtaining a lipid particle identification result of the three-dimensional scatter diagram based on the sample curve characteristics and the particle number characteristics; and outputting alarm information under the condition that the lipid particle recognition result represents that the lipid particles exist in the three-dimensional scatter diagram. By adopting the method, the cell counting accuracy can be improved.

A method for determining kinetic binding parameters of a molecular binder conjugated to a fluorophore. Repeated staining of an antigen and detection of emitted radiation generates a titration series. By fitting the emitted radiation over the titration series, kinetic binding parameters can be determined. The emitted radiation is detected by a camera, and single-pixel fitting using global analysis allows for discrimination of specific binding signal from nonspecific background at each pixel.

The application discloses a specific antibody for a CTLD1 domain of PLA2R and application thereof, and belongs to the technical field of bioengineering. The application provides a CTLD1 domain antibody of PLA2R or an antigen binding fragment thereof. The CTLD1 domain antibody or the antigen binding fragment thereof provided by the application can specifically recognize a corresponding PLA2R domain and has high affinity. In addition, the application provides a standard curve established by using the CTLD1 domain antibody of PLA2R as a standard product, and provides convenience for clinical detection of the concentration of IgG of anti-PLA2R CTLD1.

The invention discloses a specific antibody aiming at a CTLD7 structural domain of PLA2R and application of the specific antibody, and belongs to the technical field of biological engineering. The invention provides a CTLD7 structural domain antibody of PLA2R or an antigen binding fragment of the CTLD7 structural domain antibody. The CysR structural domain antibody or the antigen binding fragment thereof provided by the invention can specifically recognize the corresponding PLA2R structural domain and has relatively high affinity. Besides, the invention provides a method for establishing a standard curve by using a CTLD7 structural domain antibody of PLA2R as a standard substance, so that convenience is provided for clinical detection of concentrations of IgG resisting different epitopes of PLA2R.

The invention discloses a quantitative method of SCCP, and relates to the field of quantitative detection of short-chain chlorinated paraffin, and the method comprises a homologous substance quantitative method and a blank deduction method; the method comprises the following steps: drawing a standard curve by using configured chlorine content and total response, and checking the standard curve to obtain response factors of different family substances according to theoretical chlorine content of different family substances; and obtaining the concentration of the homologous substances by using the response of different homologous substances in the sample and using a response factor method, and the like. According to the invention, SCCP homologous substance quantification is realized, homologous substances which exist in a laboratory blank but do not exist in a sample are identified on the basis, the blank level is reduced, and the quantification accuracy of SCCP is improved.

The present application relates to a molecular detection method, which uses multi-channel single molecule mechanics technology to simultaneously manipulate multiple molecular probes to detect the analyte; the two ends of the molecular probe are connected to the carrier through the labeled coupling functional groups; the carrier is used to apply pulling force to the molecular probe. The detection process includes binding force and detection force: under the binding force, the molecular probe binds to the analyte; under the detection force, the length difference or length change curve difference of the molecular probe with or without the analyte is used as the signal strength to detect whether the analyte exists, the concentration of the analyte, the binding speed and the binding strength of the analyte to the specific structure. The present application is suitable for detecting the following analytes, such as proteins, drugs, small molecules, DNA, RNA and their complexes.

A method, kit, sensor and device for analyzing intermolecular interaction. In the method for analyzing intermolecular interaction, a rare-earth material of which the surface is modified with ligand molecules is used as an up-conversion material; the up-conversion material comes into contact with target molecules in a solution system; excitation light matching the rare-earth material is used to irradiate the solution system; in a dynamic process of continuous association / dissociation between the target molecules and the ligand molecules on the up-conversion material, the intensity of excitation light actually received by the up-conversion material continuously changes, such that the intensity of emitted light changes; and by recoding a curve of the intensity of the emitted light changing with time, kinetic constants of molecular interaction, such as an association rate constant (Kon), a dissociation rate constant (Koff), and affinity (KD), are calculated. In this way, existing technical problems of low accuracy of BLI technology and high costs of SPR technology.

The invention belongs to the technical field of in-vitro diagnosis, and particularly relates to a preparation method of a mixed calibrator for allergen sIgE detection and a calibration method for allergen sIgE detection. According to the method provided by the invention, an independent calibration reference is constructed for each sIgE index, so that the problem of system errors caused by inconsistent combination characteristics of sIgE and tIgE in heterogenous calibration is effectively solved, and the accuracy of a detection result is remarkably improved. According to the scheme, allergen specific antibodies are adopted to prepare a calibrator combination, specific calibration can be carried out on all sIgE indexes, and the defect that all indexes cannot be independently corrected through traditional heterologous calibration is overcome. The mode that all sIgE share a tIgE calibration curve in traditional heterogenous calibration is replaced, and the accuracy and stability of a detection result are remarkably improved. Quantitative calibration based on an independent calibration reference ensures the accuracy of the concentration of the calibrator, and provides a reliable basis for subsequent calibration.

This invention discloses a competitive homogeneous immunoassay method based on upconversion nanoparticles. The method involves conjugating activated upconversion nanoparticles to an antigen; enriching and purifying the upconversion nanoparticle-antigen probe; mixing the donor with specific antibodies and free antigens at different concentration gradients, followed by an immunoassay; receptor labeling; and detecting the fluorescence intensity of the reaction solution. The concentration of the antigen in the sample to be tested is obtained from the curve of the change in free antigen concentration versus fluorescence intensity, or the concentration of the target analyte is obtained at the single-particle level by counting the quantitative changes in the immune complex. This invention effectively solves the problems of high background noise and low signal-to-background ratio in resonance energy transfer (RET). By labeling the formed semi-sandwich structure immune complexes using a receptor deposition method, receptors accumulate around the immune complexes, increasing the number of receptors and shortening the distance between the donor and receptor, significantly improving RET efficiency and signal strength, thereby enhancing the sensitivity of the competitive homogeneous immunoassay.

The invention discloses a specific antibody aiming at a CTLD1 structural domain of PLA2R and application of the specific antibody, and belongs to the technical field of biological engineering. The invention provides a CTLD1 structural domain antibody of PLA2R or an antigen binding fragment of the CTLD1 structural domain antibody. The CysR structural domain antibody or the antigen binding fragment thereof provided by the invention can specifically recognize the corresponding PLA2R structural domain and has relatively high affinity. Besides, the invention provides a method for establishing a standard curve by using a CTLD1 structural domain antibody of PLA2R as a standard substance, so that convenience is provided for clinical detection of concentrations of IgG resisting different epitopes of PLA2R.

The invention relates to a method for the qualitative determination of peripherin, comprising the combining and incubating of a diluted sample with a first antibody conjugate comprising a first antibody bound to a solid phase and a second antibody conjugate comprising a biotinylated second antibody, the removal of the liquid phase and the initiation and measuring of a colour reaction. The invention also relates to a quantification of peripherin in a sample by means of a calibration curve, to the creation of a calibration curve and to a kit for peripherin determination.

The application discloses a specific antibody for a CTLD7 domain of PLA2R and application thereof, and belongs to the technical field of bioengineering. The application provides a CTLD7 domain antibody of PLA2R or an antigen binding fragment thereof. The CTLD7 domain antibody or the antigen binding fragment thereof provided by the application can specifically recognize a corresponding PLA2R domain and has high affinity. In addition, the application provides a standard curve established by using the CTLD7 domain antibody of PLA2R as a standard product, and provides convenience for clinical detection of the concentration of IgG of anti-PLA2R CTLD7.

The present application relates to the technical field of biosensing detection and natural product drug discovery, and particularly relates to a multi-target vertical fishing screening and recovery identification method for target discovery of natural products or traditional Chinese medicine extracts. The method comprises the following steps: constructing a target panel related to a target disease or biological process, and fixing at least two different decoy molecules in the panel to different channels of a bio-layer interferometry (BLI) sensor array respectively, while at least one reference channel is set; placing the sensor array in the same portion of a natural product or traditional Chinese medicine extract solution to be tested, and collecting the binding / dissociation kinetics curves in parallel; performing reference deduction, drift correction and normalization processing on the data of each channel; discriminating the corrected curves according to a preset kinetics gating criterion, outputting the decoy channel set passing the gating, and generating a confidence score to form a Top-N candidate target list; cleaning and micro-eluting the sensor surface of the candidate channel, and performing mass spectrometry, sequencing or immunology and other downstream identification on the elution recovery to establish a correspondence between the target and the binding molecule.

The invention discloses a CTLD8 structural domain specific antibody aiming at PLA2R and application of the CTLD8 structural domain specific antibody, and belongs to the technical field of biological engineering. The invention provides a CTLD8 structural domain antibody of PLA2R or an antigen binding fragment of the CTLD8 structural domain antibody. The CysR structural domain antibody or the antigen binding fragment thereof provided by the invention can specifically recognize the corresponding PLA2R structural domain and has relatively high affinity. Besides, the invention provides a method for establishing a standard curve by using a CTLD8 structural domain antibody of PLA2R as a standard substance, so that convenience is provided for clinical detection of concentrations of IgG resisting different epitopes of PLA2R.

The application discloses a detection method for drug screening and characterization based on nano-surface plasmon resonance technology, and belongs to the technical field of antibody protein affinity detection and antibody drug screening and characterization. The detection method is as follows: a NanoSPR chip is coated with a fixed ligand, an analyte to be detected is added, and then sample injection detection is carried out; a specific fitting curve equation is used to obtain a final protein-protein, antigen-antibody, DNA-protein, etc. D kinetic simulation curve, and then a corresponding equilibrium affinity constant K D is calculated. The application firstly applies the nano-surface plasmon resonance technology to the affinity detection of protein-protein, antigen-antibody, DNA-protein, etc., and analyzes the kinetics of the binding process and the dissociation process at the same time, so that the final detection result is very close to the published equilibrium affinity constant K D , which indicates that the method has very high reliability and accuracy, and can be applied to antibody drug screening and characterization.

本发明属于生物医学检测技术领域，具体涉及一种定量检测HBV preS2蛋白并鉴定血清亚型的方法。包括：采用LC‑MS / MS采集各亚型preS2蛋白特异性离子对信号；以标准曲线结合内标校正计算蛋白含量；同时提取血清HBV DNA，对preS2区进行PCR扩增和测序，与已知亚型参考序列比对确认亚型归属。本发明检测下限达100 pg / mL，可同时区分adw、adr、adr‑m、ayw、ayr五种亚型。在HBsAg阴性的隐匿性乙型肝炎患者中，该方法的preS2蛋白检出率达60%；在功能性治愈患者中，preS2蛋白检出率达70%。本发明通过质谱定量与核酸测序双重验证，为HBV特殊人群提供了可靠检测手段。

This invention relates to the field of antibodies, and particularly to an anti-Der p 1 antibody and its uses. The invention provides an anti-Der p 1 antibody comprising a heavy chain variable region and a light chain variable region. The amino acid sequence of the complementarity-determining region (CDR1) of the heavy chain variable region is as shown in SEQ ID No. 1, CDR2 of SEQ ID No. 2, and CDR3 of SEQ ID No. 3; or, the amino acid sequence of the heavy chain variable region is as shown in SEQ ID No. 8. The anti-Der p 1 antibody provided by this invention is a high-affinity, high-sensitivity monoclonal antibody. After humanizing this monoclonal antibody with IgE, it is applied to a magnetic particle chemiluminescent quantitative detection reagent for Der p 1-specific IgE of house dust mite allergens. This allows for the generation of a separately calibrated standard curve for Der p 1, achieving truly accurate and reproducible absolute quantification. It can detect Der p 1-specific IgE at a concentration of 0.1 IU / mL, and has clinical diagnostic significance for identifying allergic reactions.

This invention relates to the field of medical electro-digital data processing, and discloses a decision-making system for detecting melting curves of gene polymorphisms in hypertension medication. It collects fluorescence melting curve data of multiple gene targets; maps the melting temperature-fluorescence intensity derivative curve as graph structure nodes, and maps the melting feature associations between different gene loci as edges, constructing a multidimensional melting curve topology graph; extracts the co-fluctuation features of node peak temperature offset and edge weights and inputs them into a graph convolutional network, outputting a polymorphic combination feature vector; maps the polymorphic combination feature vector to a hypertension drug metabolism network graph model, calculates the joint decay coefficient of drug metabolic enzyme activity and receptor binding rate, and determines the type and dosage adjustment parameters for hypertension medication based on the joint decay coefficient. This invention overcomes the deficiency of single-peak independent alignment in separating overlapping peaks, achieves quantitative analysis of co-fluctuation associations of multi-gene polymorphisms, and eliminates medication bias caused by isolated qualitative matching.

The application discloses a CTLD8 domain specific antibody for PLA2R and application thereof, and belongs to the technical field of bioengineering. The application provides a CTLD8 domain antibody for PLA2R or an antigen binding fragment thereof. The CysR domain antibody or the antigen binding fragment thereof provided by the application can specifically recognize the corresponding PLA2R domain, and has high affinity. In addition, the application provides a standard curve established by using the CTLD8 domain antibody for PLA2R as a standard product, and provides convenience for clinical detection of the concentration of IgG of different epitopes of anti-PLA2R.

The present application relates to a kind of methods for quantitatively detecting target molecule X concentration, comprising: adding reporter molecule A to the reaction system comprising the target molecule X and lasting at least first given time, wherein the specific binding activity between the reporter molecule A and target molecule X;Competitive molecule B is added to the reaction system, the specific binding activity between the competitive molecule B and the reporter molecule A does not have any binding activity with the target molecule X, when the target molecule X is not present, when the competitive molecule B is combined with the reporter molecule A, it emits the fluorescence intensity L0 of given intensity;Mix the system and detect the fluorescence intensity L of the system after waiting at least second given time;In ideal concentration range, the concentration of target molecule X can be linearly related with L0-L value;The linear relationship established above is used as standard curve, and the concentration of target molecule X can be calculated from the actual measured fluorescence intensity change value L0-L.The present application also relates to the kit matched with the above method.